Gilead Sciences has announced plans to acquire Immunomedics in a deal valued at $21 billion.
Under the agreement, which has been unanimously approved by both boards of directors, Gilead will acquire the firm for $88 per share in cash, with the deal anticipated to close sometime in the fourth quarter of 2020.
The move buys Gilead access to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy), a first-in-class antibody-drug conjugate (ADC) granted accelerated approval by the US Food and Drug Administration (FDA) in April for the treatment of adults with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
Immunomedics is planning to submit a supplemental Biologics License Application (BLA) to support full approval of the drug in the US in the fourth quarter of 2020, and is also on track to file for regulatory clearance in Europe in the first half of next year.
“Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments,” said Daniel O’Day, Gilead’s chairman and chief executive.
“We look forward to welcoming the talented Immunomedics team to Gilead so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide.”
“By working with Gilead, we have the opportunity to accelerate our progress and improve care for patients in need of new therapies,” added Behzad Aghazadeh, executive chairman of Immunomedics.
By: Selina McKee
Source: Pharma Times
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.